All In Biotech

Drug Trial Radar · NCT07307794

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Characterisation of Adhesion Performance of a Newly Developed Esflurbiprofen Topical System (EFTS) - a Phase I, Open-label Study in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jan 19, 2026

Primary completion

Mar 3, 2026

Study completion Mar 12, 2026

Sponsor

Lead sponsor
Teikoku Seiyaku Co., Ltd.Industry
Sponsor type
Industry
Collaborators
SocraTec R&D GmbH; SocraMetrics GmbH; HWI pharma services GmbH; Clinsearch GmbH; CRM Biometrics GmbH
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a single-center, open-label, multiple-dose trial in healthy participants. The primary purpose of this study is to assess the adhesion of TK-254RX. Secondary purposes are to assess the safety of TK-254RX and the residual amount of the patch.

Conditions

  • Healthy Participants

Interventions

  • Esflurbiprofen Topical SystemDrug

    The total of one TK-254RX per day for 3 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Characterization of the patch adhesionTime frame: Day 1 to Day 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Deutsche Sporthochschule Köln

    Am Sportpark Muengersdorf 6, Clogne, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.